Preliminary Study of WR 33063 in the Treatment of Falciparum Malaria in Northeast Thailand

View More View Less
  • U. S. Army and Thai Medical Components, Southeast Asia Treaty Organization, Chao Phya Abhai Bhir Bejhr Hospital, Bangkok, Thailand
Restricted access

A clinical trial comparing the efficacy and toxicity of WR 33063, a phenanthrenemethanol derivative, and quinine sulfate, was undertaken in adult Thai males with Plasmodium falciparum infections hospitalized in Prachinburi, Thailand. A 6-day course of WR 33063, 1.8 g daily, in divided doses, cured 23 of 25 patients. Quinine sulfate, in a course of 1.95 g daily in divided doses for 6 days, cured 21 of 22 patients. WR 33063 treatment was accompanied by a smaller number of side effects than treatment with quinine sulfate. Hematologic and biochemical abnormalities were not detected during or following treatment with either drug. An extended trial of WR 33063 and WR 30090, a quinolinemethanol derivative, is in progress.

Author Notes

Present address: Division of Preventive Medicine, Walter Reed Army Institute of Research, Washington, D. C. 20012.